Pathologic Myopia
Cross-source consensus on Pathologic Myopia from 1 sources and 4 claims.
1 sources · 4 claims
Risks & contraindications
Comparisons
Other
Highlighted claims
- Pathologic myopia is a major global cause of irreversible blindness and visual impairment. — LED red light for atrophy and microcirculation in pathologic myopia (RAMP): study design and protocol for a multicentre randomised controlled trial
- Pathologic myopia can involve posterior staphyloma, myopic maculopathy, and myopic optic neuropathy. — LED red light for atrophy and microcirculation in pathologic myopia (RAMP): study design and protocol for a multicentre randomised controlled trial
- Current treatments for pathologic myopia mainly address established or mid-to-late-stage complications rather than preventing retinal pathology. — LED red light for atrophy and microcirculation in pathologic myopia (RAMP): study design and protocol for a multicentre randomised controlled trial
- The trial focuses on adults with pathologic myopia before severe disease onset by limiting eligibility to ages 18-55. — LED red light for atrophy and microcirculation in pathologic myopia (RAMP): study design and protocol for a multicentre randomised controlled trial